Various radiopharmacueticals
Ended Awarded Last action
- Contract number
- W81K0024F0075
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $197,174
Award facts
- Contract value 100% obligated
- $197,174.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- 2330 Stanley Rd, Fort Sam Houston, TX 78234, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $197,174 | |
| Funding Only Action | $0 | |
| Original award | $0 |
About this award
The Defense Health Agency awarded a Blanket Purchase Agreement (BPA) call valued at $197,174.40 to Sofie CO. (doing business as IBA Molecular) on October 1, 2024, for the supply of various radiopharmaceuticals. The contract is structured as a firm fixed-price award with no set-aside designation and will be performed at Fort Sam Houston, Texas, with a completion date of September 30, 2025. This BPA call draws from the Defense Health Agency's larger $6.5 million master blanket purchase agreement for pharmaceutical supplies, which enables streamlined procurement of critical radiopharmaceuticals supporting military treatment facilities across the Department of Defense healthcare system.
Sofie CO. specializes in the development, production, and delivery of molecular diagnostics and therapeutic radiopharmaceuticals, with particular expertise in positron emission tomography (PET) imaging agents used for cancer detection and neurological conditions. The company has an established track record as a key federal healthcare vendor, supplying specialized radiopharmaceuticals including PYLARIFY (piflufolastat F-18) for prostate cancer imaging, NEURACEQ (florbetaben F-18) for Alzheimer's disease imaging, and F-18 fluorodeoxyglucose for oncology applications. As a subsidiary of Sofie Biosciences headquartered in Sterling, Virginia, and registered with SAM.gov since 2001, the company maintains compliance with U.S. Nuclear Regulatory Commission and Food and Drug Administration requirements while delivering radiopharmaceuticals to federal medical treatment facilities on both routine and emergency bases.
Quick answers
Who was awarded contract W81K0024F0075?
W81K0024F0075 was awarded to Sofie CO. by Medical Command (Department of the Army) on October 1, 2024.
How much is contract W81K0024F0075 worth?
The government has obligated $197,174 on W81K0024F0075.
Which agency awarded contract W81K0024F0075?
Medical Command (Department of the Army) awarded W81K0024F0075, with funding from Defense Health Agency (Department of Defense).
Is contract W81K0024F0075 an order under another contract?
Yes. W81K0024F0075 is a BPA call under W81K0020A0016, a blanket purchase agreement.
Was contract W81K0024F0075 competed?
The extent of competition for W81K0024F0075 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award